High rate of long‐term virological response after a 1‐year course of interferon ± ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial
Éveline Boucher(Boston Scientific (United States)), Pierre Brissot(Inserm), Sylvie Jacquelinet(Inserm), Bruno Turlin(Inserm), R. Colimon, Dominique Guyader(Inserm), Christian Jacquelinet(Université Paris-Sud), V. Canva(Hôpital Claude Huriez), Yves Deugnier(Inserm)
Cited by 9
Related Papers
A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload
|Journal of Biological Chemistry|2001|1.7k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
|Molecular Pharmacology|1993|536